About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

NCT02039336·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

The Netherlands Cancer Institute

With

Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histological or cytological proof of advanced non-small cell lung cancer
Written documentation of KRAS (exon 2, 3 or 4) mutation
At least 18 years of age or older
Able and willing to give written informed consent
WHO performance status of 0 or 1

You may not be if

Symptomatic or untreated leptomeningeal disease
Symptomatic brain metastasis
Impairment of gastrointestinal function
Uncontrolled infectious disease
Left ventricular ejection fraction \< 50%
Retinal degenerative disease or with history of uveitis, retinal vein occlusion or retinal detachment

The record

StatusCompleted

PhasePhase 1–2

Taking part35

StartedApr 2014

UpdatedJul 8, 2025

Conditions

Colorectal Cancer

Where3

The Netherlands Cancer Institute
Amsterdam, Netherlands
Erasmus Medical Center Cancer Institute
Rotterdam, Netherlands
University Medical Center Utrecht
Utrecht, Netherlands

Clareo Health | Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC